NASDAQ:TRILTrillium Therapeutics Stock Price, Forecast & News

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 39.9% and is now trading at $7.26. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trillium Therapeutics.

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Trillium Therapeutics.

Trillium Therapeutics Inc (NASDAQ:TRIL) issued its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.14. View Trillium Therapeutics' earnings history.

3 equities research analysts have issued 12-month price targets for Trillium Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Trillium Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price. View analysts' price targets for Trillium Therapeutics.

Headlines about TRIL stock have been trending negative recently, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Trillium Therapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Trillium Therapeutics.

Trillium Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 6,340,000 shares, an increase of 8.4% from the June 15th total of 5,850,000 shares. Based on an average trading volume of 2,130,000 shares, the short-interest ratio is currently 3.0 days. Approximately 8.7% of the company's shares are short sold. View Trillium Therapeutics' Current Options Chain.

Some companies that are related to Trillium Therapeutics include SAGE Therapeutics (SAGE), Turning Point Therapeutics (TPTX), IGM Biosciences (IGMS), Principia Biopharma (PRNB), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Ligand Pharmaceuticals (LGND), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Xencor (XNCR), I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), Intra-Cellular Therapies (ITCI) and Myovant Sciences (MYOV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Energy Transfer LP Unit (ET), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Opko Health (OPK), TG Therapeutics (TGTX), Karyopharm Therapeutics (KPTI) and VBI Vaccines (VBIV).

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Trillium Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.26%).

TRIL stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC.

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TRIL stock can currently be purchased for approximately $7.26.

Trillium Therapeutics has a market capitalization of $605.77 million and generates $120,000.00 in revenue each year. The biotechnology company earns $-41,620,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at 416-595-0627 or via email at [email protected]